PTHLH and prostate cancer: In enzalutamide resistant prostate cancer cell lines, combination treatment of enzalutamide/PKF118-310 or enzalutamide/PTHrP(7–34) decreased cell growth compared with single treatment of PKF118-3130 or PTHrP(7–34) (S3A and S3B Fig).